Congress is pressing ActBlue over serious security questions and possible mishandling of donor validation, and the CEO has been formally asked to answer to...
The Trump administration has moved to reclassify state-licensed marijuana from Schedule I to Schedule III, a shift meant to open medical research and broaden...